CNS Drugs

, Volume 20, Issue 4, pp 311–325 | Cite as

Assessing Therapeutic Efficacy in a Progressive Disease

A Study of Donepezil in Alzheimer’s Disease
  • Peter Johannsen
  • Eric Salmon
  • Harald Hampel
  • Yikang Xu
  • Sharon Richardson
  • Suzanne Qvitzau
  • Rachel Schindler
Original Research Article

Abstract

Objective: To determine the value of continued donepezil treatment in patients with Alzheimer’s disease for whom clinical benefit was initially judged to be uncertain.

Methods: The study consisted of three phases: (i) a 12- to 24-week, pre-randomisation, open-label donepezil-treatment phase; (ii) a 12-week, randomised, double-blind, placebo-controlled phase; and (iii) a 12-week, single-blind (i.e. patient-blind) donepezil-treatment phase. Patients with mild to moderate Alzheimer’s disease received open-label treatment with donepezil (5 mg/day for 4 weeks, then 10 mg/day for the remainder of the phase) for 12–24 weeks. Patients who exhibited a decline or no change from baseline on the Mini-Mental State Examination (MMSE) and whose physician was not sufficiently certain of clinical benefit to warrant continued treatment were randomised into the double-blind phase in which patients received 12 weeks of treatment with donepezil (10 mg/day) or placebo. At the end of the double-blind phase, donepezil-treated patients continued to receive donepezil, while placebo-treated patients were rechallenged with donepezil, in a 12-week single-blind phase. Patients were assessed at the start of the double-blind phase and at weeks 6 and 12 of this phase, and at the end of the single-blind phase.

Results: Six hundred and nineteen patients completed the open-label phase; 69% showed clear clinical benefit and 31% showed uncertain benefit. 202 patients were randomised to continued donepezil treatment (n = 99) or placebo (n = 103). Differences in favour of continued donepezil versus placebo were observed in cognition and behaviour. In addition, there was a non-significant trend favouring donepezil in activities of daily living (ADL) [week 12 observed case mean treatment differences: MMSE, 1.13 (p = 0.02); Alzheimer’s Disease Assessment Scale - cognitive subscale, 0.57 (p = 0.5); the Neuropsychiatric Inventory, −3.16 (p = 0.02); Disability Assessment for Dementia scale, 3.67 (p = 0.1)].

Conclusion: Most patients showed clear clinical benefit during initial donepezil treatment. Among patients for whom clinical benefit was uncertain, improvement in cognition and behaviour were observed for those who continued donepezil treatment compared with the group switched to placebo. Initial decline or stabilisation does not necessarily indicate a lack of efficacy in Alzheimer’s disease, and the decision to discontinue treatment should be based on an evaluation of all domains (cognition, behaviour and ADL) and performed at several timepoints.

References

  1. 1.
    Hebert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003; 60: 1119–22PubMedCrossRefGoogle Scholar
  2. 2.
    Reichman WE. Current pharmacologic options for patients with Alzheimer’s disease. Ann Gen Hosp Psychiatry 2003; 2: 1PubMedCrossRefGoogle Scholar
  3. 3.
    Rogers SL, Farlow MR, Doody RS, et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Donepezil Study Group. Neurology 1998; 50: 136–45Google Scholar
  4. 4.
    Rosier M, Anand R, Cicin-Sain A, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease: international randomised controlled trial. BMJ 1999; 318: 633–8Google Scholar
  5. 5.
    Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000; 54: 2269–76Google Scholar
  6. 6.
    Areosa SA, Sherriff F. Memantine for dementia. Cochrane Database Syst Rev 2003; (3): CD003154Google Scholar
  7. 7.
    Birks JS, Harvey R. Donepezil for dementia due to Alzheimer’s disease. Cochrane Database Syst Rev 2003; (3): CD001190Google Scholar
  8. 8.
    Birks J, Grimley Evans J, Iakovidou V, et al. Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev 2000; (4): CD001191Google Scholar
  9. 9.
    Olin J, Schneider L. Galantamine for Alzheimer’s disease. Cochrane Database Syst Rev 2001; (4): CD001747Google Scholar
  10. 10.
    Mohs RC, Doody RS, Morris JC, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients [published erratum appears in Neurology 2001; 57: 1942]. Neurology 2001; 57: 481–8PubMedCrossRefGoogle Scholar
  11. 11.
    Winblad B, Engedal K, Soininen H, et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489–95PubMedCrossRefGoogle Scholar
  12. 12.
    Gauthier S, Feldman H, Hecker J, et al. Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer’s disease. Int Psychogeriatr 2002; 14: 389–404PubMedCrossRefGoogle Scholar
  13. 13.
    Feldman H, Gauthier S, Hecker J, et al. A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease [published erratum appears in Neurology 2001; vn57: 2153]. Neurology 2001; 57: 613–20PubMedCrossRefGoogle Scholar
  14. 14.
    Feldman H, Gauthier S, Hecker J, et al. Efficacy of donepezil on maintenance of activities of daily living in patients with moderate to severe Alzheimer’s disease and the effect on caregiver burden. J Am Geriatr Soc 2003; 51: 737–44PubMedCrossRefGoogle Scholar
  15. 15.
    Rogers SL, Doody RS, Pratt RD, et al. Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 2000; 10: 195–203PubMedCrossRefGoogle Scholar
  16. 16.
    Doody RS, Geldmacher DS, Gordon B, et al. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer’s disease. Arch Neurol 2001; 58: 427–33PubMedCrossRefGoogle Scholar
  17. 17.
    Geldmacher DS, Provenzano G, McRae T, et al. Donepezil is associated with delayed nursing home placement in patients with Alzheimer’s disease. J Am Geriatr Soc 2003; 51: 937–44PubMedCrossRefGoogle Scholar
  18. 18.
    Lopez OL, Becker JT, Wisniewski S, et al. Cholinesterase inhibitor treatment alters the natural history of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 2002; 72: 310–4PubMedCrossRefGoogle Scholar
  19. 19.
    Wimo A, Winblad B, Engedal K, et al. An economic evaluation of donepezil in mild to moderate Alzheimer’s disease: results of a 1-year, double-blind, randomized trial. Dement Geriatr Cogn Disord 2003; 15: 44–54PubMedCrossRefGoogle Scholar
  20. 20.
    Feldman H, Gauthier S, Hecker J, et al. Economic evaluation of donepezil in moderate to severe Alzheimer’s disease. Neurology 2004 Aug 24; 63: 644–50PubMedCrossRefGoogle Scholar
  21. 21.
    Doody RS, Stevens JC, Beck C, et al. Practice parameter: management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2001; 56: 1154–66Google Scholar
  22. 22.
    Folstein MF, Folstein SE, McHugh PR. ‘Mini-mental state’: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189–98PubMedCrossRefGoogle Scholar
  23. 23.
    Drugs of Alzheimer’s disease: full guidance [online]. Available from URL: http://www.nice.org.uk [Accessed 2003 Dec 23]
  24. 24.
    Mayeux R, Sano M. Treatment of Alzheimer’s disease. N Engl J Med 1999; 341: 1670–9PubMedCrossRefGoogle Scholar
  25. 25.
    Winblad B, Brodaty H, Gauthier S, et al. Pharmacotherapy of Alzheimer’s disease: is there a need to redefine treatment success? Int J Geriatr Psychiatry 2001; 16: 653–66PubMedCrossRefGoogle Scholar
  26. 26.
    Diagnostic and statistical manual of mental disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994Google Scholar
  27. 27.
    McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer’s disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer’s Disease. Neurology 1984; 34: 939–44PubMedCrossRefGoogle Scholar
  28. 28.
    World Medical Association Declaration of Helsinki. Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997; 277: 925–6CrossRefGoogle Scholar
  29. 29.
    Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer’s disease. Am J Psychiatry 1984; 141: 1356–64PubMedGoogle Scholar
  30. 30.
    Cummings JL, Mega M, Gray K, et al. The neuropsychiatrie inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44: 2308–14PubMedCrossRefGoogle Scholar
  31. 31.
    Gelinas I, Gauthier L, Mclntyre M, et al. Development of a functional measure for persons with Alzheimer’s disease: the disability assessment for dementia. Am J Occup Ther 1999; 53: 471–81PubMedCrossRefGoogle Scholar
  32. 32.
    Galasko D. An integrated approach to the management of Alzheimer’s disease: assessing cognition, function and behaviour. Eur J Neurol 1998; 5Suppl. 4: S9–17CrossRefGoogle Scholar
  33. 33.
    Rockwood K, Graham JE, Fay S. Goal setting and attainment in Alzheimer’s disease patients treated with donepezil. J Neurol Neurosurg Psychiatry 2002; 73: 500–7PubMedCrossRefGoogle Scholar
  34. 34.
    Berger F, Winkel M, Hampel H, et al. Individual Symptom Score (IndiSS): a pragmatic approach to clinically relevant outcomes in dementia studies [abstract]. J Am Geriatr Soc 2003; 51: S167Google Scholar
  35. 35.
    Matthews H, Korkey J, Wilkinson D, et al. Donepezil in Alzheimer’s disease: eighteen month results from Southampton memory clinic. Int J Geriatr Psychiatry 2000; 15: 713–20PubMedCrossRefGoogle Scholar
  36. 36.
    Rymer S, Salloway S, Norton L, et al. Impaired awareness, behavior disturbance, and caregiver burden in Alzheimer disease. Alzheimer Dis Assoc Disord 2002; 16: 248–53PubMedCrossRefGoogle Scholar
  37. 37.
    Steele C, Rovner B, Chase GA, et al. Psychiatric symptoms and nursing home placement of patients with Alzheimer’s disease. Am J Psychiatry 1990; 147: 1049–51PubMedGoogle Scholar
  38. 38.
    Leon J, Cheng CK, Neumann PJ. Alzheimer’s disease care: costs and potential savings. Health Aff (Millwood) 1998; 17: 206–16CrossRefGoogle Scholar
  39. 39.
    Auriacombe S, Pere J-J, Loria-Kanza Y, et al. Efficacy and safety of rivastigmine in patients with Alzheimer’s disease who failed to benefit from treatment with donepezil. Curr Med Res Opin 2002; 18: 129–38PubMedCrossRefGoogle Scholar
  40. 40.
    Morris JC, Farlow MR, Ferris SH, et al. Therapeutic continuity in Alzheimer’s disease: switching patients to galantamine. Clin Ther 2001; 23Suppl. A: A1–39PubMedCrossRefGoogle Scholar
  41. 41.
    Pratt RD, Perdomo CA, Surick IW, et al. Donepezil: tolerability and safety in Alzheimer’s disease. Int J Clin Pract 2002; 56: 710–7PubMedGoogle Scholar

Copyright information

© Adis Data Information BV 2006

Authors and Affiliations

  • Peter Johannsen
    • 1
  • Eric Salmon
    • 2
  • Harald Hampel
    • 3
  • Yikang Xu
    • 4
  • Sharon Richardson
    • 5
  • Suzanne Qvitzau
    • 6
  • Rachel Schindler
    • 7
  1. 1.Section 6702, Memory Disorder Unit, Department of NeurologyCopenhagen Memory Clinic, RigshospitaletCopenhagenDenmark
  2. 2.Department of NeurologyUniversity HospitalLiègeBelgium
  3. 3.Department of PsychiatryLudwig Maximilian UniversityMunichGermany
  4. 4.Clinical Data Operations, Pfizer Global PharmaceuticalsPfizer Inc.New YorkUSA
  5. 5.Eisai Inc.TeaneckUSA
  6. 6.Pfizer DenmarkCopenhagenDenmark
  7. 7.Worldwide NeurosciencesPfizer Inc.New YorkUSA

Personalised recommendations